Tavares, IsabelMoreira, LucianaCosta, Paulo PinhoLobato, Luísa2018-03-222019-04-012017-03Amyloid. 2017 Mar;24(sup1):153-154. doi: 10.1080/13506129.2017.1281119.1350-6129http://hdl.handle.net/10400.18/5437Background: Fibrinogen A alpha-chain (AFib) amyloidosis is a rare and late-onset disease, that result from amyloidogenic autosomal dominant mutations in the gene-encoding AFib (FGA). Patients invariably develop chronic kidney disease (CKD), typically progressing to end-stage renal failure within 5 years of recognition of renal involvement [1]. In Portugal, four apparently unrelated patients with AFib amyloidosis were identified in the district of Braga, Northern Portugal. They all carried the FGA p.Glu545Val mutation, three were heterozygous and one homozygous [2,3]. This observation led us to assess the prevalence of AFibE526V (p.Glu545Val) amyloidosis among Portuguese patients undergoing hemodialysis in the same district, through genetic screening for the FGA p.Glu545Val mutation.engFibrinogen A alpha-chain (AFib) AmyloidosisRare DiseaseDoenças Genéticasjournal article10.1080/13506129.2017.1281119